
































Radioiodoterapia ambulatorial de alta dose
Laura Sterian Ward1
The number of patients who need radioiodine therapy (RIT) after surgical excision of thyroid tumors has been rising in Brazil, as well as the number of differentiated 
thyroid carcinomas detected by ultrasonography. Likewise most international 
guidelines, the consensus on thyroid cancer from the Department of Thyroid of 
the Sociedade Brasileira de Endocrinologia & Metabologia (Brazilian Society of 
Endocrinology and Metabolism, SBEM) recommends radioiodine remnant ablation 
to all patients submitted to a total thyroidectomy, with the exception of a very-low-
risk patient (T1N0M0, with single tumor completely excised) (1). The rationale is 
to destroy any remaining tumor and to improve the ease of follow-up by eliminating 
all follicular cells, thereby making serum thyroglobulin (Tg) dosage a more specific 
marker of recurrent or persistent disease. The procedure is not mandatory in patients 
categorized as low risk and very low risk and can be accomplished, in some instances, 
by a single 131I dose of 30 mCi (equivalent to 1100 Mbq), which delivers about 10 
whole-body rads to the patient, although most endocrinologists prefer to administer 
a dose of 100 mCi. Brazilian regulations impose the hospitalization of all patients 
treated with doses higher than 30 mCi; however, unfortunately, the number of 
facilities enabled to administrate high-dose radioiodine has not increased in the same 
proportion of the cases in need of these doses, and the limited number of available 
ward beds has aggravated the patients’ troubles. Because we usually withhold thyroid 
hormone therapy, waiting for the radioiodine ablation of thyroid remnants after 
surgery, many patients have remained hypothyroid for much longer than the expected 
four to six weeks necessary to elevate their serum TSH levels (1). Also, withdrawal of 
thyroid hormone has been the standard procedure over the last decades to increase 
TSH, thereby enhancing the sensitivity of Tg measurement and increasing radioiodine 
uptake by recurrent thyroid tumors (1). Hence, high-risk patients submitted to control 
whole-body scans frequently have to endure the ordeal of hypothyroidism and the risk 
of tumor cell stimulation due to elevated TSH levels, which many times takes much 
longer than expected.
The publication of Sapienza and cols. (2), demonstrating the feasibility of high-
dose radioiodine outpatient therapy, holds out hopes for a new scenario for Brazilian 
patients. The authors did not detect any significant environmental impact of the ad-
ministration of 100 to 150 mCi of 131I to 20 outpatients. They monitored 27 family 
caregiver members, who were given personal dosimeters and were asked not to modify 
their common routine. In 26 out of these individuals, the dose of 131I received was 
lower than 1 mSv during the observation period. Even the one individual, who dis-
obeying the medical recommendations, remained close to the patient for a long time, 
received a dose of 131I (2,8 mSv) that did not exceed the 5,0 mSv value considered 
acceptable for caregivers (2). Although we need to increase the number of patients 
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High-dose radioiodine outpatient therapy
treated with the author’s protocol and it is necessary 
to study its application in different cities and by other 
groups or services that treat thyroid cancer patients, in 
order to confirm its larger feasibility in Brazil, this first 
report provides compelling evidences on the safety of 
high-dose administration on an outpatient basis.
The safety of the dose administration differs from 
country to country, according to the local interpreta-
tion of the International Atomic Energy Agency (IAEA) 
recommendations. The cornerstone criteria are dose 
limits for the public and dose constraints for relatives 
and caregivers. Different measures have been adopted, 
according to the International Basic Safety Standards 
(BSS), in the construal of maximum activity allowed for 
patients and caregivers in different countries and even 
in hospitals from the same country. A series of recent 
publications have reported actual measurements and 
external dose rates, as well as contamination potential 
that indicates that most countries are overly restrictive 
(3-7). Using a mathematical model, Coover and cols. 
(8) developed charts that took occupancy factors into 
account. The results indicate that most outpatients un-
dergoing RIT for thyroid cancer may be safely treated 
with 7400 MBq (200 mCi) or more (8). A recent simu-
lation study published by a Brazilian group, which used 
the Visual Monte Carlo radiation transport code and 
the female voxel phantom to calculate organ and effec-
tive irradiation doses delivered by RIT also concluded 
for the safety of a 300 mCi (11100 MBq) dose to a 
patient receiving daily care at home (9). 
The Nuclear Regulatory Commission revised the 
criteria for RIT in the United States in 1997 and, the-
oretically, allowed patients requiring doses as high as 
9,250 MBq (250 mCi) to be discharged from the hos-
pital immediately after receiving the radioiodine dose 
(10). Currently, in Europe, in the United States and 
in some Latin American countries, such as Argentina, 
competent and cooperative patients are routinely dis-
charged with activities as high as 8000 MBq (216 mCi), 
provided that they abide certain restrictions. The cur-
rent dose constraints proposed in a number of publica-
tions include: children and fetuses, 1 mSv; adults up 
to 60 years of age, 3 mSv; adults over 60 years of age, 
15 mSv; third persons, such as drivers of vehicles used 
for patient transport or general public, 0.3 mSv. 
Sapienza and cols. (2) add data to previous reports 
on the safety, cost-effectiveness and patient acceptance 
of high dose 131I therapy delivered on an outpatient ba-
sis (5-7). The levels of contamination were lower than 
regulatory limits. Patients and caregivers had no diffi-
culty complying with requirements for radiation safety. 
Concerns about persons who provide direct care to the 
patient actually following regulations will always exist, 
but these results suggest that, for a well-selected and 
screened group of thyroid cancer patients receiving 
outpatient RIT, the procedure is safe and does not sub-
ject any family member or member of the public to the 
risk of exceeding accepted limits for public exposure to 
radiation. 
The implication of the study is the urgent need for 
revision of our public policies and the prompt imple-
mentation of larger outpatient RIT protocols through-
out the country. This should make the therapy more 
convenient and widely available, as well as reduce pa-
tient care costs.
Disclosure: No potential conflict of interest relevant to this article 
was reported.
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